Financial Consulate’s Royalty Pharma RPRX Stock Holding History

Financial Consulate’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.1K	Hold	1,000	–	–	0.01%	326
2026 Q1	$48K	Sell	1,000 -1	-0.1%	-$44	0.01%	334
2025 Q4	$38.7K	Buy	1,001 +1	+0.1%	+$38	0.01%	360
2025 Q3	$35.3K	Buy	+1,000	New	+$36.2K	0.01%	363
2023 Q2	–	Sell	-7,300	Closed	-$263K	–	98
2023 Q1	$263K	Hold	7,300	–	–	0.09%	104
2022 Q4	$288K	Hold	7,300	–	–	0.1%	112
2022 Q3	$293K	Hold	7,300	–	–	0.12%	91
2022 Q2	$307K	Hold	7,300	–	–	0.14%	93
2022 Q1	$284K	Hold	7,300	–	–	0.11%	104
2021 Q4	$291K	Buy	+7,300	New	+$284K	0.1%	110
2021 Q1	–	Sell	-4,000	Closed	-$200K	–	124
2020 Q4	$200K	Buy	+4,000	New	+$170K	0.09%	109

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Consulate's RPRX Position: Q2 2026 in Review

Financial Consulate held its Royalty Pharma (RPRX) position steady in Q2 2026 at 1,000 shares worth $56.1K. The position accounts for 0.01% of the portfolio, ranked #326.

Financial Consulate first reported a position in RPRX in Q4 2020 and has held it in 11 quarters since. The position peaked at $307K in Q2 2022. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Financial Consulate held 1,000 shares of Royalty Pharma worth $56.1K as of Q2 2026.
Financial Consulate left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 0.01% of Financial Consulate's portfolio in Q2 2026, its #326 holding.
Financial Consulate first reported a position in Royalty Pharma in Q4 2020 and has held it in 11 quarters since.
Financial Consulate's Royalty Pharma position peaked at $307K in Q2 2022.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.